We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
84 hedge funds and large institutions have $730M invested in Crescent Biopharma in 2018 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 31 increasing their positions, 21 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
51% more call options, than puts
Call options by funds: $1.53M | Put options by funds: $1.01M
48% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 21
3% more capital invested
Capital invested by funds: $707M → $730M (+$23.8M)
0.03% more ownership
Funds ownership: 1.06% → 1.09% (+0.03%)
0% more funds holding
Funds holding: 84 → 84 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 24
Holders
84
Holders Change
–
Holders Change %
0%
% of All Funds
1.92%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
24
Increased
31
Reduced
21
Closed
24
Calls
$1.53M
Puts
$1.01M
Net Calls
+$519K
Net Calls Change
-$3.72M
Top Buyers
| 1 |
BlackRock
New York
|
+$27.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.92M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$8.68M |
| 4 |
O
OppenheimerFunds
New York
|
+$7.85M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$5.7M |
Top Sellers
| 1 |
CCI
Columbus Circle Investors
|
-$9.11M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$4.68M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$4.35M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$4.06M |
| 5 |
Goldman Sachs
New York
|
-$3.54M |
